Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects approximately
4.5 million people in the United States. The mainstays of current pharmacotherapy for …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers
of neurodegenerative dementias, enormous advancement has taken place in the field, …

Alzheimer disease (AD) and Parkinson disease (PD) are the most common neurodegenerative
disorders. For both diseases, early intervention is thought to be essential to the success …

Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have
been linked to Nasu-Hakola disease, Alzheimer’s disease (AD), Parkinson’s disease, …

Background The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and
phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Introduction Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic
workup of several neurological brain diseases. Reluctance to perform the procedure is …

Importance One characteristic histopathological event in Alzheimer disease (AD) is cerebral
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …

Mutations in three genes (PSEN1, PSEN2, and APP) have been identified in patients with
early-onset (<65years) Alzheimer's disease (AD). We performed a screening for mutations in …

Introduction Lumbar puncture (LP) is increasingly performed in memory clinics. We investigated
patient‐acceptance of LP, incidence of and risk factors for post‐LP complications in …